Cargando…
Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World
Comirnaty (BNT162b2) and Spikevax (mRNA-1273) COVID-19 vaccines encode a full-length SARS-CoV-2 Spike (S) protein. To evaluate whether the S-protein expressed following treatment with the two vaccines differs in the real-world context, two cell lines were treated for 24 h with two concentrations of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144021/ https://www.ncbi.nlm.nih.gov/pubmed/37112792 http://dx.doi.org/10.3390/vaccines11040879 |
_version_ | 1785034002989580288 |
---|---|
author | Cari, Luigi Naghavi Alhosseini, Mahdieh Mencacci, Antonella Migliorati, Graziella Nocentini, Giuseppe |
author_facet | Cari, Luigi Naghavi Alhosseini, Mahdieh Mencacci, Antonella Migliorati, Graziella Nocentini, Giuseppe |
author_sort | Cari, Luigi |
collection | PubMed |
description | Comirnaty (BNT162b2) and Spikevax (mRNA-1273) COVID-19 vaccines encode a full-length SARS-CoV-2 Spike (S) protein. To evaluate whether the S-protein expressed following treatment with the two vaccines differs in the real-world context, two cell lines were treated for 24 h with two concentrations of each vaccine, and the expression of the S-protein was evaluated using flow cytometry and ELISA. Vaccines were obtained from three vaccination centers in Perugia (Italy) that provided us with residual vaccines present in vials after administration. Interestingly, the S-protein was detected not only on the cell membrane but also in the supernatant. The expression was dose-dependent only in Spikevax-treated cells. Furthermore, the S-protein expression levels in both cells and supernatant were much higher in Spikewax-than in Comirnaty-treated cells. Differences in S-protein expression levels following vaccine treatment may be attributed to variations in the efficacy of lipid nanoparticles, differences in mRNA translation rates and/or loss of some lipid nanoparticles’ properties and mRNA integrity during transport, storage, or dilution, and may contribute to explaining the slight differences in the efficacy and safety observed between the Comirnaty and Spikevax vaccines. |
format | Online Article Text |
id | pubmed-10144021 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101440212023-04-29 Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World Cari, Luigi Naghavi Alhosseini, Mahdieh Mencacci, Antonella Migliorati, Graziella Nocentini, Giuseppe Vaccines (Basel) Brief Report Comirnaty (BNT162b2) and Spikevax (mRNA-1273) COVID-19 vaccines encode a full-length SARS-CoV-2 Spike (S) protein. To evaluate whether the S-protein expressed following treatment with the two vaccines differs in the real-world context, two cell lines were treated for 24 h with two concentrations of each vaccine, and the expression of the S-protein was evaluated using flow cytometry and ELISA. Vaccines were obtained from three vaccination centers in Perugia (Italy) that provided us with residual vaccines present in vials after administration. Interestingly, the S-protein was detected not only on the cell membrane but also in the supernatant. The expression was dose-dependent only in Spikevax-treated cells. Furthermore, the S-protein expression levels in both cells and supernatant were much higher in Spikewax-than in Comirnaty-treated cells. Differences in S-protein expression levels following vaccine treatment may be attributed to variations in the efficacy of lipid nanoparticles, differences in mRNA translation rates and/or loss of some lipid nanoparticles’ properties and mRNA integrity during transport, storage, or dilution, and may contribute to explaining the slight differences in the efficacy and safety observed between the Comirnaty and Spikevax vaccines. MDPI 2023-04-21 /pmc/articles/PMC10144021/ /pubmed/37112792 http://dx.doi.org/10.3390/vaccines11040879 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Cari, Luigi Naghavi Alhosseini, Mahdieh Mencacci, Antonella Migliorati, Graziella Nocentini, Giuseppe Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World |
title | Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World |
title_full | Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World |
title_fullStr | Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World |
title_full_unstemmed | Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World |
title_short | Differences in the Expression Levels of SARS-CoV-2 Spike Protein in Cells Treated with mRNA-Based COVID-19 Vaccines: A Study on Vaccines from the Real World |
title_sort | differences in the expression levels of sars-cov-2 spike protein in cells treated with mrna-based covid-19 vaccines: a study on vaccines from the real world |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144021/ https://www.ncbi.nlm.nih.gov/pubmed/37112792 http://dx.doi.org/10.3390/vaccines11040879 |
work_keys_str_mv | AT cariluigi differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld AT naghavialhosseinimahdieh differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld AT mencacciantonella differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld AT miglioratigraziella differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld AT nocentinigiuseppe differencesintheexpressionlevelsofsarscov2spikeproteinincellstreatedwithmrnabasedcovid19vaccinesastudyonvaccinesfromtherealworld |